NT0100
/ NeuBase Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 14, 2020
NeuBase Therapeutics reports financial results for the second fiscal quarter of 2020
(GlobeNewswire)
- "We expect to announce the lead candidate for the NT0100 Program for HD by the end of calendar year 2020, followed by the initiation of IND-enabling studies during the first half of calendar year 2021."
New trial • CNS Disorders • Genetic Disorders • Huntington's Disease
1 to 1
Of
1
Go to page
1